Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia.
Serum neopterin (Np), beta 2-microglobulin (beta 2-M), and 2',5'-adenylate (2',5'A) levels and intracellular 2',5'A and human Mx (Hu-Mx) protein synthesis were measured in 20-24 chronic myeloid leukemia patients before and during 1 year of IFN-alpha treatment and in a further 8-9 patients before and at the end of the first and second treatment weeks only. Univariate analysis showed that IFN-alpha increased Np and 2',5'A serum levels and intracellular concentrations of 2',5'A and Hu-Mx significantly from the end of the first week to month 12 of therapy. The biologic marker profiles were similar in cytogenetic responders and nonresponders, as well as in patients treated with IFN-alpha early (< 12 months from diagnosis) or late (after > 12 months standard chemotherapy). Further, there were no differences in the short-term (first 14 days) or long-term (during 12 month therapy) induction of the biologic markers irrespective of whether IFN-alpha 2a or IFN-alpha 2b was given. Because multivariate analysis revealed no significant interactions between cytogenetic response, time to treatment, and type of IFN-alpha used, increments in intracellular 2',5'A and Hu-Mx protein were similar at all study times for all factor combinations tested. Np levels varied significantly only during the first 14 therapy days; changes in serum 2',5'A were never statistically significant.(ABSTRACT TRUNCATED AT 250 WORDS)
Liberati
A M
AM
Istituto di Medicina Interna e Scienze Oncologiche, Policlinico Monteluce Perugia, Italy.
Horisberger
M A
MA
Garofani
P
P
De Angelis
V
V
Ferrajoli
A
A
Di Clemente
F
F
Caricchi
P
P
Adiuto
D
D
Fedeli
L
L
Palumbo
B
B
D000249:Adenosine Monophosphate / Q000097:blood*; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000096:biosynthesis; D001708:Biopterins / Q000031:analogs & derivatives* / Q000097:blood; D005260:Female; D019204:GTP-Binding Proteins / Q000096:biosynthesis; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D064547:Myxovirus Resistance Proteins; D019798:Neopterin; D014176:Protein Biosynthesis; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin / Q000378:metabolism*
D000998:Antiviral Agents; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D064547:Myxovirus Resistance Proteins; D011994:Recombinant Proteins; D001613:beta 2-Microglobulin; D001708:Biopterins; D000249:Adenosine Monophosphate; D019798:Neopterin; D019204:GTP-Binding Proteins